title: Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
abstract: BACKGROUND
  Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined.
  
  
  METHODS
  Patients with advanced HIV-associated KS were randomly assigned to receive paclitaxel at a dose of 100 mg/m2 intravenously (iv) every 2 weeks or PLD at a dose of 20 mg/m2 iv every 3 weeks. The KS Functional Assessment of HIV (FAHI) quality of life instrument was used before and after every other treatment cycle.
  
  
  RESULTS
  The study included 73 analyzable patients enrolled between 1998 and 2002, including 36 in the paclitaxel arm and 37 in the PLD arm; 73% of patients received highly active antiretroviral therapy (HAART) and 32% had an undetectable viral load (<400 copies/mL). Treatment was associated with significant improvements in pain (P=.024) and swelling (P<.001). Of the 36 patients who reported that pain interfered with their normal work or activities at baseline, 25 (69%) improved. Of the 41 patients who reported swelling at baseline, 38 (93%) improved. Comparing the paclitaxel and PLD arms revealed comparable response rates (56% vs 46%; P=.49), median progression-free survival (17.5 months vs 12.2 months; P=.66), and 2-year survival rates (79% vs 78%; P=.75), but somewhat more grade 3 to 5 toxicity for paclitaxel (84% vs 66%; P=.077).
  
  
  CONCLUSIONS
  Treatment with either paclitaxel or PLD appears to produce significant improvements in pain and swelling in patients with advanced, symptomatic, HIV-associated KS treated in the HAART era.
authors.affiliation: Department of Medicine, Northwestern University, Chicago, Illinois 60611, USA. m-cianfrocca@northwestern.edu
authors.forename: Mary
authors.initials: M
authors.lastname: Cianfrocca
authors.forename: Sandra
authors.initials: S
authors.lastname: Lee
authors.forename: Jamie
authors.initials: J
authors.lastname: Von Roenn
authors.forename: Anil
authors.initials: A
authors.lastname: Tulpule
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Dezube
authors.forename: David M
authors.initials: DM
authors.lastname: Aboulafia
authors.forename: Richard F
authors.initials: RF
authors.lastname: Ambinder
authors.forename: Jeannette Y
authors.initials: JY
authors.lastname: Lee
authors.forename: Susan E
authors.initials: SE
authors.lastname: Krown
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sparano
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D057239:Early Termination of Clinical Trials; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011788:Quality of Life; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology / Q000821:virology
chemical_list: C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin; D017239:Paclitaxel